Qtern is saxagliptin and dapagliflozin.
- TRADE NAMES: Onglyza (Bristol-Myers Squibb); Qtern (AstraZeneca)
- INDICATIONS: Type II diabetes mellitus
- CLASS: Antidiabetic, Dipeptidyl peptidase-4 (DPP-4) (gliptin) inhibitor, Hypoglycemic (antihyperglycemic) agent
- HALF-LIFE: 2.5–3.1 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
ACE inhibitors, Alcohol, Aprepitant, Beta blockers, Bexarotene, Colchicine, Conivaptan, Corticosteroids, CYP3A4 inducers, Darunavir, Dasatinib, Delavirdine, Diazoxide, Diuretics, Efavirenz, Estradiol, Estrogens, Hypoglycemic agents, Indinavir, Ketoconazole, Lapatinib, MAO inhibitors, Oxcarbazepine, P-glycoprotein inhibitors and inducers, Pegvisomant, Pioglitazone, Rifapentine, Somatropin, Strong CYP3A4/5 inhibitors, Telithromycin, Terbinafine, Testosterone, Voriconazole
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of saxagliptin in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/05/2026
